Last reviewed · How we verify
Cetrorelix and Leuprolide
Cetrorelix and leuprolide work together to suppress the pituitary-gonadal axis by blocking GnRH signaling, preventing premature luteinizing hormone surge during controlled ovarian hyperstimulation for assisted reproduction.
Cetrorelix and leuprolide work together to suppress the pituitary-gonadal axis by blocking GnRH signaling, preventing premature luteinizing hormone surge during controlled ovarian hyperstimulation for assisted reproduction. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF), Prevention of premature luteinizing hormone surge during fertility treatment.
At a glance
| Generic name | Cetrorelix and Leuprolide |
|---|---|
| Sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
| Drug class | GnRH antagonist and GnRH agonist combination |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Cetrorelix is a GnRH antagonist that rapidly suppresses luteinizing hormone (LH) secretion, while leuprolide is a GnRH agonist that causes initial stimulation followed by downregulation of the pituitary. Together, they prevent the natural LH surge that would otherwise trigger ovulation prematurely during in vitro fertilization (IVF) cycles, allowing controlled egg retrieval.
Approved indications
- Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF)
- Prevention of premature luteinizing hormone surge during fertility treatment
Common side effects
- Headache
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Key clinical trials
- Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection (PHASE4)
- Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation (NA)
- The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization. (PHASE4)
- Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1 (NA)
- Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity (NA)
- GnRH Agonist and Antagonists in an Oocyte Donation Program (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: